Drugmakers will conduct lung-cancer trials under single protocol

06/12/2013 | Nature (free content)

A new project aims to create a "master protocol" that will involve multiple pharmaceutical companies using one experimental plan to test multiple lung-cancer treatments in hundreds of clinics throughout the US, speeding up the drug-approval process. The plan will match drugmakers with patients whose tumors are most genetically relevant to the tested treatments. "The drive is to make the whole process of personalized medicine more efficient," said Eric Rubin, vice president of oncology clinical research at Merck. If the project succeeds, it may be applied to additional cancers.

View Full Article in:

Nature (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT